OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/ALK
Lung Cancer — Non-Small Cell (NSCLC)ALK Clinical Trials
ALK gene fusions — most commonly EML4-ALK — occur in 3–5% of NSCLC and are more prevalent in younger, never-smoking patients. Alectinib and lorlatinib are current first-line standards; sequential ALK inhibitors are used upon acquired resistance. Active trials explore next-generation inhibitors and combinations for lorlatinib-resistant disease.
Top recruiting ALK Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Nuvalent Inc.
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
Yang Hong
Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
Dr Arvindran A/L Alaga
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Intergroupe Francophone de Cancerologie Thoracique
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd.
More ALK Lung Cancer — Non-Small Cell (NSCLC) trials
See all in search →8 international trials (no US sites)
FDA-approved therapies for ALK Lung Cancer — Non-Small Cell (NSCLC)
Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.